To evaluate trends in the utilization of active surveillance (AS) in a nationally representative cancer database. AS has been increasingly recognized as an effective strategy for patients with small renal masses but little is known about national usage patterns.
We identified patients with clinical T1a renal masses within the National Cancer Database in 2010 through 2014. Patients were classified according to initial management strategy received including AS, surgery, ablation, or other treatment. We characterized time trends in the use of AS vs definitive therapy and examined clinical and socio-demographic determinants of AS among patients with small renal masses using multivariable logistic regression models.
We identified 59,189 patients who satisfied the inclusion criteria. Of the total cohort, 1733 (2.9%) individuals received initial management with AS, while 57,456 (97.1%) received definitive treatment. Surveillance rates remained below 5% in all years. On multivariate analysis, patient age (OR: 1.08, 95% CI 1.08-1.09), smaller tumor size of <2 cm vs ≥2 cm (OR: 2.43, 95% CI: 2.20-2.7, P < .0001), management at an academic center vs community center (OR: 2.05, 95% CI: 1.83-2.29), and African American vs Caucasian race (OR: 1.56, 95% CI:1.35-1.80) were independently associated with use of AS as initial management.
In a representative national cohort of patients with small renal masses, we observed clinical and facility-level differences in the utilization of active surveillance in patients with T1a renal masses. Further investigation is warranted to better understand the forces underlying initial management decisions for patients with small renal masses.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010.J Urol. 2014; 191: 1665
- Rising incidence of small renal masses: a need to reassess treatment effect.J Natl Cancer Inst. 2006; 98: 1331
- Cancer statistics, 2017.CA Cancer J Clin. 2017; 67: 7
- Solid renal tumors: an analysis of pathological features related to tumor size.J Urol. 2003; 170: 2217
- Adverse pathologic characteristics in the small renal mass: implications for active surveillance.Can J Urol. 2017; 24: 8759
- Renal tumor biopsy for small renal masses: a single-center 13-year experience.Eur Urol. 2015; 68: 1007
- The natural history of incidentally detected small renal masses.Cancer. 2004; 100: 738
- Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.Eur Urol. 2015; 68: 408
- Adverse health outcomes associated with surgical management of the small renal mass.J Urol. 2014; 191: 301
- Active surveillance for small renal masses.Rev Urol. 2012; 14: 13
- The natural history of observed enhancing renal masses: meta-analysis and review of the world literature.J Urol. 2006; 175: 425
- Active surveillance for selected patients with renal masses: updated results with long-term follow-up.Cancer. 2007; 110: 1010
- Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index?.BJU Int. 2009; 103: 1492
- Observation should be considered as an alternative in management of renal masses in older and comorbid patients.Eur Urol. 2009; 55: 1419
- Small renal parenchymal neoplasms: further observations on growth.Radiology. 1995; 197: 589
- Renal mass and localized renal cancer: AUA guideline.J Urol. 2017; 198: 520
- The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.Ann Surg Oncol. 2008; 15: 683
- Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.Cancer. 2012; 118: 997
- Active surveillance of small renal masses: progression patterns of early stage kidney cancer.Eur Urol. 2011; 60: 39
- Active surveillance is superior to radical nephrectomy and equivalent to partial nephrectomy for preserving renal function in patients with small renal masses: results from the DISSRM registry.J Urol. 2015; 194: 903
- National treatment trends among older patients with T1-localized renal cell carcinoma.Urol Oncol. 2017; 35: 113.e15
- Management of small kidney cancers in the new millennium: contemporary trends and outcomes in a population-based cohort.JAMA Surg. 2015; 150: 664
- Treatment of patients with small renal masses: a survey of the American Urological Association.J Urol. 2011; 185: 407
- The association between evaluation at academic centers and the likelihood of expectant management in low-risk prostate cancer.Urology. 2016; 96: 128
- Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: results from a national survey of radiation oncologists and urologists.Med Care. 2014; 52: 579
- Racial/ethnic disparity in treatment for prostate cancer: does cancer severity matter?.Urology. 2017; 99: 76
- Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.Prostate. 2011; 71: 985
- "Cutting" on cancer: attitudes about cancer spread and surgery among primary care patients in the U.S.A.Soc Sci Med. 2011; 73: 1669
Published online: July 27, 2018
Accepted: July 2, 2018
Received in revised form: June 29, 2018
Received: May 1, 2018
Financial Disclosure:The authors declare that they have no relevant financial interests.
Presentations:Accepted for presentation: 2017 New England Section of the American Urological Association Meeting; 2018 American Urological Association Annual Meeting.
© 2018 Published by Elsevier Inc.